- Home
- Automated
- List of product information
- NUROFEN EXPRESS CAPLETS 684MG [SIN14367P]
NUROFEN EXPRESS CAPLETS 684MG [SIN14367P]
Active ingredients: NUROFEN EXPRESS CAPLETS 684MG
Product Info
NUROFEN EXPRESS CAPLETS 684MG
[SIN14367P]
Product information
Active Ingredient and Strength | IBUPROFEN ACID 400 MG EQV IBUPROFEN LYSINE - 684 MG |
Dosage Form | TABLET, FILM COATED |
Manufacturer and Country | RECKITT BENCKISER HEALTHCARE INTERNATIONAL LIMITED - UNITED KINGDOM |
Registration Number | SIN14367P |
Licence Holder | RECKITT BENCKISER (SINGAPORE) PTE LTD |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | M01AE01 |
Indications
Nurofen Express is indicated for the relief of pain such as headache, migraine pain, dental pain, period pain, rheumatic pain, muscular pain and backache. It also relieves fever such as fever associated with cold & flu.
Recommended Dose
For oral administration and short-term use only.
Adults, the elderly and children over 12 years:
The lowest effective dose should be used for the shortest duration necessary to relieve symptoms. The patient should consult a doctor if symptoms persist or worsen, or if the product is required for more than 10 days.
Take 1 caplet with water, up to three times a day as required. Leave at least 4 hours between doses.
Do not take more than 3 caplets in any 24 hour period.
Contraindications
Hypersensitivity to ibuprofen or any of the excipients in the product.
Patients who have previously shown hypersensitivity reactions (e.g. asthma, rhinitis, angioedema, or urticaria) in response to aspirin or other non-steroidal anti-inflammatory drugs.
Active or history of recurrent peptic ulcer/haemorrhage (two or more distinct episodes of proven ulceration or bleeding)
History of gastrointestinal bleeding or perforation, related to previous NSAIDs therapy.
Severe heart failure, renal failure or hepatic failure (see Special warning and precaution for use – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information)
Last trimester of pregnancy (see Pregnancy and lactation – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information)
In patients who have recently undergone coronary artery bypass graft (CABG) surgery and revascularization procedures.
